Positive basophil histamine release assay predicts insufficient response to standard-dosed omalizumab in patients with chronic spontaneous urticaria

Publikation: Bidrag til tidsskrift › Letter › Forskning › fagfællebedømt

Dokumenter

  • Fulltext

    Forlagets udgivne version, 347 KB, PDF-dokument

OriginalsprogEngelsk
TidsskriftClinical and Experimental Allergy
Vol/bind53
Udgave nummer12
Sider (fra-til)1318-1321
ISSN0954-7894
DOI
StatusUdgivet - 2023

Bibliografisk note

Funding Information:
Katrine Baumann was supported by the BRIDGE—Translational Excellence Programme ( bridge.ku.dk ) at the Faculty of Health and Medical Sciences, University of Copenhagen, funded by the Novo Nordisk Foundation. Grant agreement no. NNF20SA0064340 (2021 fellows). This study benefitted from the GALEN network of Urticaria Centers of Reference and Excellence (UCAREs, https://ga2len‐ucare.com/ ). 2

ID: 373887988